Recursion Pharmaceuticals (RXRX) Competitors

$2.98 -0.07 (-2.14%)

As of 01:57 PM Eastern

RXRX vs. RYTM, TGTX, PTGX, SYRE, and MIRM

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.61	-$196.54M	-$3.13	N/A
Recursion Pharmaceuticals	$65.74M	23.98	-$644.76M	-$1.20	N/A

Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, indicating a potential upside of 45.96%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 172.27%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 18 mentions for Rhythm Pharmaceuticals and 10 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.46 beat Rhythm Pharmaceuticals' score of -0.26 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rhythm Pharmaceuticals beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to TG Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

TG Therapeutics has a net margin of 65.95% compared to Recursion Pharmaceuticals' net margin of -842.95%. TG Therapeutics' return on equity of 88.73% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	23.98	-$644.76M	-$1.20	N/A
TG Therapeutics	$616.29M	9.93	$447.18M	$2.86	13.97

Recursion Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Recursion Pharmaceuticals currently has a consensus target price of $8.10, indicating a potential upside of 172.27%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 31.36%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 4 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.79 beat Recursion Pharmaceuticals' score of 0.46 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Recursion Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Protagonist Therapeutics has a net margin of -154.88% compared to Recursion Pharmaceuticals' net margin of -842.95%. Protagonist Therapeutics' return on equity of -17.76% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Protagonist Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	23.98	-$644.76M	-$1.20	N/A
Protagonist Therapeutics	$46.02M	143.87	-$130.15M	-$1.81	N/A

Recursion Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Recursion Pharmaceuticals currently has a consensus target price of $8.10, indicating a potential upside of 172.27%. Protagonist Therapeutics has a consensus target price of $113.69, indicating a potential upside of 10.43%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 10 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.46 beat Protagonist Therapeutics' score of 0.22 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spyre Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Spyre Therapeutics' return on equity of -42.88% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Recursion Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, indicating that its share price is 212% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	23.98	-$644.76M	-$1.20	N/A
Spyre Therapeutics	$890K	7,174.35	-$155.20M	-$2.08	N/A

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 10 articles in the media. Spyre Therapeutics' average media sentiment score of 1.03 beat Recursion Pharmaceuticals' score of 0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Recursion Pharmaceuticals currently has a consensus target price of $8.10, indicating a potential upside of 172.27%. Spyre Therapeutics has a consensus target price of $90.25, indicating a potential upside of 22.74%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Spyre Therapeutics beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Recursion Pharmaceuticals' net margin of -842.95%. Mirum Pharmaceuticals' return on equity of -11.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Recursion Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	23.98	-$644.76M	-$1.20	N/A
Mirum Pharmaceuticals	$521.31M	12.39	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 12 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 22 mentions for Mirum Pharmaceuticals and 10 mentions for Recursion Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Recursion Pharmaceuticals' score of 0.46 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Recursion Pharmaceuticals currently has a consensus target price of $8.10, indicating a potential upside of 172.27%. Mirum Pharmaceuticals has a consensus target price of $136.42, indicating a potential upside of 28.84%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57B	$2.99B	$6.24B	$12.30B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-2.47	18.04	20.39	25.31
Price / Sales	23.98	258.60	541.96	72.69
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.54	4.29	9.79	6.90
Net Income	-$644.76M	$72.19M	$3.56B	$333.98M
7 Day Performance	-10.39%	-2.50%	0.43%	-0.27%
1 Month Performance	-20.67%	-2.80%	-0.87%	1.56%
1 Year Performance	-30.00%	40.57%	35.95%	32.45%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	3.0647 of 5 stars	$2.98 -2.1%	$8.10 +172.3%	-29.5%	$1.57B	$65.74M	N/A	400	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.146 of 5 stars	$94.17 -2.1%	$131.81 +40.0%	+63.5%	$6.59B	$189.76M	N/A	140	Analyst Revision
TGTX TG Therapeutics	4.3005 of 5 stars	$42.86 -0.4%	$52.50 +22.5%	+22.1%	$6.59B	$616.29M	14.99	290
PTGX Protagonist Therapeutics	1.8544 of 5 stars	$99.36 +0.5%	$113.69 +14.4%	+141.1%	$6.36B	$46.02M	N/A	120	Positive News Insider Trade
SYRE Spyre Therapeutics	2.7185 of 5 stars	$75.04 +2.7%	$89.08 +18.7%	+411.1%	$6.35B	$890K	N/A	73	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. RYTM, TGTX, PTGX, SYRE, and MIRM

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to TG Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. RYTM, TGTX, PTGX, SYRE, and MIRM

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Is RYTM or RXRX more profitable?

Which has better earnings & valuation, RYTM or RXRX?

Which has more risk & volatility, RYTM or RXRX?

Do analysts prefer RYTM or RXRX?

Do institutionals and insiders hold more shares of RYTM or RXRX?

Does the media prefer RYTM or RXRX?

Summary

How does Recursion Pharmaceuticals compare to TG Therapeutics?

Is RXRX or TGTX more profitable?

Which has stronger valuation & earnings, RXRX or TGTX?

Which has more volatility & risk, RXRX or TGTX?

Do analysts recommend RXRX or TGTX?

Do insiders & institutionals believe in RXRX or TGTX?

Does the media favor RXRX or TGTX?

Summary

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Is RXRX or PTGX more profitable?

Which has stronger valuation & earnings, RXRX or PTGX?

Which has more volatility & risk, RXRX or PTGX?

Do analysts recommend RXRX or PTGX?

Do insiders & institutionals believe in RXRX or PTGX?

Does the media favor RXRX or PTGX?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Do institutionals & insiders believe in RXRX or SYRE?

Is RXRX or SYRE more profitable?

Which has more risk & volatility, RXRX or SYRE?

Which has higher valuation and earnings, RXRX or SYRE?

Does the media favor RXRX or SYRE?

Do analysts recommend RXRX or SYRE?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Do institutionals & insiders believe in RXRX or MIRM?

Is RXRX or MIRM more profitable?

Which has more risk & volatility, RXRX or MIRM?

Which has higher valuation and earnings, RXRX or MIRM?

Does the media favor RXRX or MIRM?

Do analysts recommend RXRX or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools